Chen Pengfei, Chen Zhuhong, Pan Deng, Miao Lina, Shi Yujiao, Guo Ming, Du Jianpeng
Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Cardiovascular Diseases Center, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Front Neurol. 2022 Sep 8;13:934512. doi: 10.3389/fneur.2022.934512. eCollection 2022.
Atrial fibrillation (AF) is a risk factor for cognitive dysfunction. Although catheter ablation (CA) is one of the main treatments for AF, whether it can improve cognitive function in patients with AF remains unclear. We conducted a systematic review and meta-analysis to evaluate the cognitive outcome post-CA procedure.
Two investigators independently searched the PubMed, EMBASE, Web of Science, CNKI, WanFang, and VIP databases from inception to September 2021 for all the potentially eligible studies. The outcomes of interest included dementia or cognitive disorder through scoring or recognized classification criteria. Heterogeneity was determined by using Cochrane's Q test and calculating the . A random-effects model was used to incorporate the potential effects of heterogeneity. The Newcastle-Ottawa Scale (NOS) was used to assess the methodological quality of each included study, and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) method was adopted to evaluate the quality of evidence.
Thirteen studies including 40,868 patients were included, among which 12,086 patients received AF ablation. Meta-analysis indicated that patients with AF ablation had a lower risk of dementia incidence in comparison to patients with AF without ablation [hazard ratio (HR): 0.60, 95% CI: 0.43 to 0.84, = 0.003 = 40%]. Significant differences were observed in the incidence of new-onset dementia [risk ratio (RR): 0.43, 95% CI: 0.28 to 0.65, < 0.0001 = 84%]; the changes in the Montreal Cognitive Assessment (MoCA) score [weighted mean difference (WMD): 1.00, 95% CI: 0.36 to 1.64, < 0.005 = 0%] and Mini-Mental State Examination (MMSE) score (WMD: 0.98, 95% CI: 0.69 to 1.26, < 0.00001 = 0%]. However, in subgroup analysis, we did not observe significant changes in MoCA score at < 3 months (WMD: 1.20, 95% CI: -0.19 to 2.58, = 0.09 = 50%) and changes in cognitive function scores between the radiofrequency group and cryoballoon group [standard mean difference (SMD): 0.39, 95% CI: -0.47 to 1.24, = 0.38 = 87%]. The NOS indicated that included studies were moderate to high quality, while the quality of evidence assessed by GRADE was low in 2 and very low in 2.
We analyzed the related cognitive outcomes after AF ablation. In the overall population, AF ablation had a positive trend for improving cognitive function at >3 months post-procedure. However, AF ablation might not be related to the improvement of cognitive function at < 3 months.
https://www.crd.york.ac.uk/PROSPERO/, identifier: CRD42021285198.
心房颤动(AF)是认知功能障碍的一个危险因素。尽管导管消融(CA)是AF的主要治疗方法之一,但它是否能改善AF患者的认知功能仍不清楚。我们进行了一项系统评价和荟萃分析,以评估CA术后的认知结局。
两名研究者独立检索了从数据库建立至2021年9月的PubMed、EMBASE、Web of Science、中国知网、万方和维普数据库,以查找所有可能符合条件的研究。感兴趣的结局包括通过评分或公认的分类标准得出的痴呆或认知障碍。采用Cochrane's Q检验并计算I²来确定异质性。使用随机效应模型纳入异质性的潜在影响。采用纽卡斯尔-渥太华量表(NOS)评估每项纳入研究的方法学质量,并采用推荐分级的评估、制定与评价(GRADE)方法评估证据质量。
纳入了13项研究,共40868例患者,其中12086例患者接受了AF消融。荟萃分析表明,与未接受消融的AF患者相比,接受AF消融的患者痴呆发病率风险较低[风险比(HR):0.60,95%置信区间(CI):0.43至0.84,P = 0.003,I² = 40%]。新发痴呆的发病率[风险比(RR):0.43,95% CI:0.28至0.65,P < 0.0001,I² = 84%]、蒙特利尔认知评估(MoCA)评分的变化[加权均数差(WMD):1.00,95% CI:0.36至1.64,P < 0.005,I² = 0%]和简易精神状态检查表(MMSE)评分(WMD:0.98,95% CI:0.69至1.26,P < 0.00001,I² = 0%)均存在显著差异。然而,在亚组分析中,我们未观察到术后<3个月时MoCA评分的显著变化(WMD:1.20,95% CI:-0.19至2.58,P = 0.09,I² = 50%),以及射频组和冷冻球囊组之间认知功能评分的变化[标准化均数差(SMD):0.39,95% CI:-0.47至1.24,P = 0.38,I² = 87%]。NOS表明纳入的研究质量为中等至高,而GRADE评估的证据质量有2项为低,2项为极低。
我们分析了AF消融术后的相关认知结局。在总体人群中,AF消融在术后>3个月时有改善认知功能的积极趋势。然而,AF消融可能与术后<3个月时认知功能的改善无关。